Abstract
Cancer is the second most common cause of death in western countries today. Despite of modern therapeutic approaches leading to longer survival rates, the only cure for the most solid tumors is resection of the entire tumor. However, cure is generally only possible in patients with limited disease without distant metastases. Therefore, detection of precancerous conditions or early cancer stages is crucial to reduce the mortality of cancer.
To date, blood-based biomarkers which can be assayed within the patient’s clinical chemistry workup are the most frequently used markers for detecting cancer. Unfortunately, most of these markers are neither able to detect precancerous conditions nor early cancer stages at the required high sensitivity and specificity levels to be of use in any screening procedure.
Recently, RNA fragments derived from the noncoding RNA U2 snRNA were detected at elevated levels among others in the blood of patients suffering from pancreatic, colorectal, and non-small-cell lung cancer as compared to noncancerous controls. Sensitivity and specificity levels reached with the proposed U2 snRNA fragment detection assays were well above the levels reported for current noninvasive blood-based tumor markers used in clinical routine. U2 snRNA fragments proved to be highly stable in the serum and plasma from cancer patients and could be detected by a simple routine PCR-based assay, crucial requirements for an analyte to be successfully implemented into a clinical routine diagnostic procedure. Importantly, the fragments were also found to be significantly elevated in a fraction of early colon and lung cancer patients. Therefore, detection of U2 snRNA fragments in the blood cannot only be regarded as a novel strategy to detect cancer but may also hold promise for detecting some cancer types at a curable stage.
Abbreviations
- Ago:
-
Argonaute Protein
- AUC:
-
Area Under the Curve
- BSiR:
-
Branch Site-Interacting Region
- CA19-9:
-
Carbohydrate Antigen 19-9
- CEA:
-
Carcinoembryonic Antigen
- CI:
-
Confidence Interval
- COPD:
-
Chronic Obstructive Pulmonary Disease
- CRC:
-
Colorectal Carcinoma
- Ct:
-
Cycle Threshold
- Cyfra 21-1:
-
Cytokeratin 19 Fragments
- EDTA:
-
Ethylenediaminetetraacetic Acid
- miRNA:
-
MicroRNA
- ncRNA:
-
Noncoding RNA
- NGS:
-
Next-Generation Sequencing
- NSCLC:
-
Non-small-Cell Lung Cancer
- PDAC:
-
Pancreatic Ductal Adenocarcinoma
- piRNA:
-
PIWI-Associated RNAs
- pre-mRNA:
-
Precursor Messenger RNA
- PSA:
-
Prostate-Specific Antigen
- qRT-PCR:
-
Quantitative Real-Time Polymerase Chain Reaction
- RNP:
-
Ribonucleoprotein Particle
- ROC:
-
Receiver Operating Characteristic
- rRNA:
-
Ribosomal RNA
- siRNA:
-
Small Interfering RNA
- snoRNA:
-
Small Nucleolar RNAs
- snRNA:
-
Small Nuclear RNAs
- snRNP:
-
Small Nuclear Ribonucleoprotein Particle
- tRNA:
-
Transfer RNA
- UICC:
-
Union Internationale Contre Le Cancer
References
Arroyo JD, Chevillet JR, Kroh EM, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A. 2011;108:5003–8. doi:10.1073/pnas.1019055108.
Bach D, Fuereder J, Karbiener M, et al. Comprehensive analysis of alterations in the miRNome in response to photodynamic treatment. J Photochem Photobiol B. 2013;120C:74–81. doi:10.1016/j.jphotobiol.2013.01.012.
Baraniskin A, Nöpel-DĂ¼nnebacke S, Ahrens M, et al. Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for pancreatic and colorectal adenocarcinoma. Int J cancer. 2013;132:E48–57. doi:10.1002/ijc.27791.
Biggiogera M, Bottone MG, Martin TE, et al. Still immunodetectable nuclear RNPs are extruded from the cytoplasm of spontaneously apoptotic thymocytes. Exp Cell Res. 1997;234:512–20.
Brenner H, Hoffmeister M, Brenner G, et al. Expected reduction of colorectal cancer incidence within 8 years after introduction of the German screening colonoscopy programme: estimates based on 1,875,708 screening colonoscopies. Eur J Cancer (Oxford, England: 1990). 2009;45:2027–33. doi:10.1016/j.ejca.2009.02.017.
Burroughs AM, Ando Y, de Hoon ML, et al. Deep-sequencing of human Argonaute-associated small RNAs provides insight into miRNA sorting and reveals Argonaute association with RNA fragments of diverse origin. RNA Biol. 2011;8:158–77. doi:10.4161/rna.8.1.14300.
Chen J, Yao D, Li Y, et al. Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma. Int J Mol Med. 2013;32:557–67. doi:10.3892/ijmm.2013.1424.
Fearon EF, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–67.
Halicka HD, Bedner E, Darzynkiewicz Z. Segregation of RNA and separate packaging of DNA and RNA in apoptotic bodies during apoptosis. Exp Cell Res. 2000;260:248–56.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.
Jemal A, Bray F, Ferlay J. Global cancer statistics. 2011;61:69–90. doi:10.3322/caac.20107. Available
Jones CI, Zabolotskaya MV, King AJ, et al. Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma. Br J Cancer. 2012;107:1987–96. doi:10.1038/bjc.2012.525.
Kambach C, Walke S, Young R, et al. Crystal structures of two Sm protein complexes and their implications for the assembly of the spliceosomal snRNPs. Cell. 1999;96:375–87.
Li A, Yu J, Kim H, et al. MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Clin Cancer Res Off J Am Assoc Cancer Res. 2013. doi:10.1158/1078-0432.CCR-12-3092.
Liao J, Yu L, Mei Y, et al. Small nucleolar RNA signatures as biomarkers for non-small-cell lung cancer. Mol Cancer. 2010;9:198. doi:10.1186/1476-4598-9-198.
Madhavan D, Cuk K, Burwinkel B, Yang R. Cancer diagnosis and prognosis decoded by blood-based circulating microRNA signatures. Front Genet. 2013;4:116. doi:10.3389/fgene.2013.00116.
Mazières J, Catherinne C, Delfour O, et al. Alternative processing of the U2 small nuclear RNA produces a 19-22 nt fragment with relevance for the detection of non-small cell lung cancer in human serum. PLoS One. 2013;8:e60134. doi:10.1371/journal.pone.0060134.
Palma J, Yaddanapudi SC, Pigati L, et al. MicroRNAs are exported from malignant cells in customized particles. Nucleic Acids Res. 2012;40:9125–38. doi:10.1093/nar/gks656.
Patent application SNRNA RNU2 – 1 ALS TUMORMARKER, European patent office, PCT/EP 2012/064321, 22 July 2011
Pigati L, Yaddanapudi SCS, Iyengar R, et al. Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS One. 2010;5:e13515.
Takeshita N, Hoshino I, Mori M, et al. Serum microRNA expression profile: miR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma. Br J Cancer. 2013;108:644–52. doi:10.1038/bjc.2013.8.
Taylor DP, Cannon-Albright LA, Sweeney C, et al. Comparison of compliance for colorectal cancer screening and surveillance by colonoscopy based on risk. Genet Med Off J Am Coll Med Genet. 2011;13:737–43.
Valadi H, Ekström K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9:654–9. doi:10.1038/ncb1596.
Will CL, LĂ¼hrmann R. Splicing of a rare class of introns by the U12-dependent spliceosome. Biol Chem. 2005;386:713–24. doi:10.1515/BC.2005.084.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media Dordrecht
About this entry
Cite this entry
Hahn, S.A., Zoellner, H., Maghnouj, A., Vangala, D.B. (2015). U2 Small Nuclear RNA as a Biomarker in Cancer. In: Preedy, V., Patel, V. (eds) Biomarkers in Cancer. Biomarkers in Disease: Methods, Discoveries and Applications. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-7681-4_6
Download citation
DOI: https://doi.org/10.1007/978-94-007-7681-4_6
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-7680-7
Online ISBN: 978-94-007-7681-4
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences